Since the PD-1/PD-L1 pathway exerts immunosuppressive effects within the tumor microenvironment and promotes malignant progression [38], disruption of this pathway by combinatorial treatment is likely to induce beneficial anti-tumor effects. The gene discussed is CD274; the disease is neoplasm.